Outcomes of pediatric patients with oncologic disease or following hematopoietic stem cell transplant supported on extracorporeal membrane oxygenation: The PEDECOR experience.

Abstract:

BACKGROUND:Outcomes for patients with oncologic disease and/or after hematopoietic stem cell transplant (HSCT) requiring intensive care unit admission have improved, but indications for and outcomes after extracorporeal membrane oxygenation (ECMO) support in this population are poorly characterized. PROCEDURE:We analyzed data from consecutive patients < 18 years with oncologic disease and/or after HSCT reported to a pediatric ECMO registry by nine pediatric centers in the United States between 2011 and 2018. RESULTS:We identified 18 ECMO patients with oncologic disease and/or HSCT, and 415 ECMO controls matched with a propensity score algorithm based on age, gender, race, severity of illness at admission, and reason for ECMO. The primary indication for ECMO was respiratory failure in 66.7% in the oncologic disease and/or HSCT group, and in 70.7% in the matched ECMO control group. Eleven of 18 patients survived to hospital discharge (61.1%), similar to the matched control group (60.8%), P = 0.979. Children with oncologic disease and/or HSCT had lower mean platelet counts during ECMO and received higher volumes of platelets compared with the control group, mean 14.6 mL/kg/day (standard deviations [SD], 9.8) versus mean 9.3 mL/kg/day (SD, 10.4), P = 0.001. Of the 11 surviving children with oncologic disease and/or HSCT, five sustained new neurologic disorders (45.5%) versus 45 of 222 (20.3%) in the control group, P = 0.061. Bleeding complications were similar in the two groups. CONCLUSIONS:Outcomes of patients with oncologic disease and/or HSCT supported on ECMO in the current era are not significantly different compared with matched ECMO controls and are improved from previously published reports.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Steppan DA,Coleman RD,Viamonte HK,Hanson SJ,Carroll MK,Klein OR,Cooke KR,Spinella PC,Steiner ME,Loftis LL,Bembea MM,Pediatric ECMO (PediECMO) subgroup of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network and

doi

10.1002/pbc.28403

subject

Has Abstract

pub_date

2020-10-01 00:00:00

pages

e28403

issue

10

eissn

1545-5009

issn

1545-5017

journal_volume

67

pub_type

杂志文章,多中心研究
  • Incidence and outcomes of patients with late recurrence of Wilms' tumor.

    abstract:BACKGROUND:Most relapses from Wilms' tumor occur within 2 years from diagnosis. This study aims to describe the incidence and outcome of patients who experienced a late recurrence (LR) more than 5 years after diagnosis across several clinical trials, and to develop evidence-based recommendations for follow-up surveilla...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1002/pbc.24604

    authors: Malogolowkin M,Spreafico F,Dome JS,van Tinteren H,Pritchard-Jones K,van den Heuvel-Eibrink MM,Bergeron C,de Kraker J,Graf N,COG Renal Tumors Committee and the SIOP Renal Tumor Study Group.

    更新日期:2013-10-01 00:00:00

  • Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia.

    abstract:BACKGROUND:Extramedullary infiltration (EMI) is an occasional clinical symptom in childhood acute myelogenous leukemia (AML), but there is considerable controversy regarding the prognostic significance of EMI in AML. PROCEDURE:We evaluated the frequency and prognostic significance of EMI at diagnosis of AML in childre...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20824

    authors: Kobayashi R,Tawa A,Hanada R,Horibe K,Tsuchida M,Tsukimoto I,Japanese childhood AML cooperative study group.

    更新日期:2007-04-01 00:00:00

  • Beta-thalassemia major births after National Screening Program in Taiwan.

    abstract:OBJECTIVE:A National Thalassemia Screening Program was adopted in Taiwan in 1993. This report examined that program's results and impact. METHODS:Patients with beta-thalassemia major born between 1994 and 2003 were recruited through the help of all thalassemia clinics in Taiwan. A structured questionnaire was designed...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21185

    authors: Chern JP,Lin KH,Lu MY,Lin DT,Jou ST,Yang YL,Chang HH,Su S,Lin KS

    更新日期:2008-01-01 00:00:00

  • Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients.

    abstract:BACKGROUND:Pneumocystis jirovecii, formerly carinii, pneumonia (PCP) poses a life-threatening risk to oncology patients. The use of trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis virtually eliminates the risk of infection; however, many patients cannot tolerate TMP-SMZ. We performed a retrospective analysis to det...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21287

    authors: Kim SY,Dabb AA,Glenn DJ,Snyder KM,Chuk MK,Loeb DM

    更新日期:2008-04-01 00:00:00

  • Prevalence of Symptomatic and Asymptomatic Thrombosis in Pediatric Oncology Patients With Tunneled Central Venous Catheters.

    abstract:BACKGROUND:Pediatric oncology patients with tunneled central venous catheters (CVCs) are at increased risk to develop venous thromboembolic events (VTEs), but the true prevalence of (a)symptomatic VTE is unknown. Aim of this study was to evaluate the prevalence of (a)symptomatic VTE in pediatric oncology patients with ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1002/pbc.26036

    authors: Schoot RA,van de Wetering MD,Stijnen T,Tissing WJ,Michiels E,Abbink FC,Raphael MF,Heij HA,Zwaan M,Lieverst JA,Caron HN,van Ommen H,DCOG-Aristocaths Supportive Care Working Group.

    更新日期:2016-08-01 00:00:00

  • Sirolimus therapy in the treatment of pseudomyogenic hemangioendothelioma.

    abstract::Pseudomyogenic hemangioendothelioma (PMH) is a rare, mostly indolent vascular tumor. Extensive cases are treated with amputation as chemotherapy seems to be ineffective. Recently, promising results were published using mammalian target of rapamycin (mTOR) inhibitors in tumors of vascular origin. Here, we present a cas...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26781

    authors: Gabor KM,Sapi Z,Tiszlavicz LG,Fige A,Bereczki C,Bartyik K

    更新日期:2018-02-01 00:00:00

  • Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting.

    abstract::Treatment recommendations for endemic Burkitt lymphoma (BL) in settings with only minimum requirements for curative treatment (PODC setting 1) are described. The reported cure rate for endemic BL is usually <50%. Facilities within setting 1 differ. Three treatment schedules are proposed based on: (1) when accurate sta...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,实务指引

    doi:10.1002/pbc.24407

    authors: Hesseling P,Israels T,Harif M,Chantada G,Molyneux E,Pediatric Oncology in Developing Countries.

    更新日期:2013-03-01 00:00:00

  • Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

    abstract:BACKGROUND:SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. PROCEDURES:SCH 727965 was tested against the PPTP in vitro panel using 96 hours exposure at concentra...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24073

    authors: Gorlick R,Kolb EA,Houghton PJ,Morton CL,Neale G,Keir ST,Carol H,Lock R,Phelps D,Kang MH,Reynolds CP,Maris JM,Billups C,Smith MA

    更新日期:2012-12-15 00:00:00

  • Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma.

    abstract::A rare case of primary intestinal T-cell lymphoma (ITL) of an 8-year-old boy is reported. Medium- to large-sized tumor cells were betaF1+, CD3+, CD8+. TIA-1+, but CD4-, CD5-, CD30-, CD56-, CD20-, CD79a-, TdT-, consistent with an intraepithelial lymphocyte (IEL) origin. They showed monoclonal rearrangement of the T-cel...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22330

    authors: Friedrich C,Schrum J,Chott A,Janka-Schaub G,Kabisch H

    更新日期:2010-04-01 00:00:00

  • Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols.

    abstract::Adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) constitute a distinct population from children and older adults. Based on patterns of referral, they may be treated by either paediatric or adult oncologists. As a group, AYA with ALL have a worse survival and event-free survival (EFS) compare...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20776

    authors: Ramanujachar R,Richards S,Hann I,Webb D

    更新日期:2006-11-01 00:00:00

  • Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance.

    abstract:BACKGROUND:Thyroid dysfunction has been reported in up to 52% of patients 1.4 years after treatment with (131) I-Metaiodobenzylguanidine (MIBG) in children with neuroblastoma (NBL), despite the use of potassium-iodide (KI). Our aim was to investigate if the incidence and severity of thyroid damage increases in time. M...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24681

    authors: Clement SC,van Eck-Smit BL,van Trotsenburg AS,Kremer LC,Tytgat GA,van Santen HM

    更新日期:2013-11-01 00:00:00

  • Chemotherapy responsiveness in a patient with multiply relapsed ameloblastic fibro-odontosarcoma of the maxilla.

    abstract::Ameloblastic fibro-odontosarcoma (AFOS) is an extremely rare malignant odontogenic tumor. Complete surgical excision is the treatment of choice. Deaths due to disease recurrence and/or progression are documented. Here, we report the case of a 15-year-old female with multiple recurrent AFOS. She responded to chemothera...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25627

    authors: Gatz SA,Thway K,Mandeville H,Kerawala C,MacVicar D,Chisholm J

    更新日期:2015-11-01 00:00:00

  • Reversible Fanconi syndrome in a pediatric patient on deferasirox.

    abstract::Deferasirox (Exjade®, Novartis) is a widely used oral iron chelator for the treatment of patients with iron overload due to chronic transfusion therapy for diseases such as β-thalassemia and sickle cell disease. Renal side effects of deferasirox are common and include non-progressive increases in serum creatinine, how...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22711

    authors: Rheault MN,Bechtel H,Neglia JP,Kashtan CE

    更新日期:2011-04-01 00:00:00

  • Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors.

    abstract:BACKGROUND:To determine the maximum-tolerated duration and dose-limiting toxicity of a daily schedule of orally administered cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. METHODS:Patients received oral cyclophosphamide (50 mg/m2/dose) in the morning followed ...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.10456

    authors: Bowers DC,Aquino VM,Leavey PJ,Bash RO,Journeycake JM,Tomlinson G,Mulne AF,Haynes HJ,Winick NJ

    更新日期:2004-01-01 00:00:00

  • Clinical management of pediatric aggressive fibromatosis involving the mandible.

    abstract:BACKGROUND:Pediatric aggressive fibromatosis (AF) is a rare, benign tumor with locally infiltrative growth. Therefore, how to prevent reoccurrence while maintaining the mandible contour and continuity as much as possible is very important when the mandible is involved. PROCEDURE:We selected 10 pediatric patients with ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24145

    authors: Zhou Y,Zhang Z,Fu H,Qiu W,Wang L,He Y

    更新日期:2012-10-01 00:00:00

  • In-hospital mortality of hematopoietic stem cell transplantation among children with nonmalignancies: A nationwide study in the United States from 2000 to 2012.

    abstract:BACKGROUND:Hematopoietic stem cell transplant (HSCT) can cure or alleviate a wide range of nonmalignant childhood conditions. However, few studies have examined longitudinal national trends of frequency or short-term complications of HSCT before 2006 when an HSCT became a reportable procedure by US law. By using a US n...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27626

    authors: Takahashi T,Pereda MA,Bala N,Nagarajan S

    更新日期:2019-06-01 00:00:00

  • Young siblings of children with cancer deserve care and a personalized approach.

    abstract::The youngest siblings may be both emotionally vulnerable and often neglected members of the family of a childhood cancer patient. The prompt identification of signs of distress in these subjects allows trained caregivers to intervene with personalized, age-appropriate, attention, and care. A narrative approach, based ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21056

    authors: Massimo LM,Wiley TJ

    更新日期:2008-03-01 00:00:00

  • Delivery of radiation therapy in resource-limited settings: A pilot quality assessment study.

    abstract::Progress has been made in resource-limited countries in treating acute lymphoblastic leukemia, but advances in solid malignancies have been slower. Multidisciplinary care coordination is challenging, assessing adherence to guidelines through quality improvement initiatives is essential. We characterized deviations fro...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26480

    authors: Power-Hays A,Friedrich P,Fernandez G,Cruz NA,Marcus K,Rodriguez-Galindo C,Collado L

    更新日期:2017-08-01 00:00:00

  • A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.

    abstract::Chronic granulomatous disease (CGD) is an immune deficiency characterized by defective neutrophil function and increased risk of life-threatening infections. Allogeneic hematopoietic cell transplantation is curative for CGD, and conditioning regimen impacts transplant-related outcomes. We report a single-center prospe...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.28030

    authors: Bhatt ST,Schulz G,Hente M,Slater A,Murray L,Shenoy S,Bednarski JJ

    更新日期:2020-01-01 00:00:00

  • Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom.

    abstract:BACKGROUND:Anthracycline cardiomyopathy is of concern in children treated for acute myeloid leukaemia (AML), but there are few data on the incidence and natural history of cardiotoxicity after AML treatment in the United Kingdom, where regimens have included high anthracycline exposure. PROCEDURE:Prevalence and predic...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22908

    authors: Temming P,Qureshi A,Hardt J,Leiper AD,Levitt G,Ancliff PJ,Webb DK

    更新日期:2011-04-01 00:00:00

  • Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology.

    abstract::Bridging the survival gap for children with cancer, between those (the great majority) in low and middle income countries (LMIC) and their economically advantaged counterparts, is a challenge that has been addressed by twinning institutions in high income countries with centers in LMIC. The long-established partnershi...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.24802

    authors: Barr RD,Antillón Klussmann F,Baez F,Bonilla M,Moreno B,Navarrete M,Nieves R,Peña A,Conter V,De Alarcón P,Howard SC,Ribeiro RC,Rodriguez-Galindo C,Valsecchi MG,Biondi A,Velez G,Tognoni G,Cavalli F,Masera G

    更新日期:2014-02-01 00:00:00

  • Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.

    abstract:BACKGROUND:The aims of this study were to define the mRNA expression profiles of MYCN, DDX1, TrkA, and TrkC in biopsy tumor samples from 64 Brazilian patients with neuroblastomas of different risk stages and to correlate altered expression with prognostic values. PROCEDURE:Patients were retrospectively classified into...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22823

    authors: de Souza DR,Sanabani SS,de Souza AC,Filho Odone V,Epelman S,Bendit I

    更新日期:2011-05-01 00:00:00

  • Successful treatment of a child with T/myeloid acute bilineal leukemia associated with TLX3/BCL11B fusion and 9q deletion.

    abstract::Acute bilineal leukemias are rare and are commonly associated with t(9;22) and MLL abnormalities. Herein, we report a pediatric case of bilineal T/myeloid acute leukemia associated with del (9q)(q13q22) and TLX3/BCL11B fusion due to the cryptic t(5;14)(q35;32). FISH studies confirmed the TLX3/BCL11B fusion in both the...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22850

    authors: Oliveira JL,Kumar R,Khan SP,Law ME,Erickson-Johnson M,Oliveira AM,Ketterling RP,Dogan A

    更新日期:2011-03-01 00:00:00

  • Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.

    abstract::Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.20648

    authors: Rodriguez V,Anderson PM,Trotz BA,Arndt CA,Allen JA,Khan SP

    更新日期:2007-08-01 00:00:00

  • Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia.

    abstract:BACKGROUND:Glucocorticoids and asparaginase, used to treat acute lymphoblastic leukemia (ALL), can cause hypertriglyceridemia. We compared triglyceride levels, risk factors, and associated toxicities in two ALL trials at St. Jude Children's Research Hospital with identical glucocorticoid regimens, but different asparag...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28040

    authors: Finch ER,Smith CA,Yang W,Liu Y,Kornegay NM,Panetta JC,Crews KR,Molinelli AR,Cheng C,Pei D,Ramsey LB,Karol SE,Inaba H,Sandlund JT,Metzger M,Evans WE,Jeha S,Pui CH,Relling MV

    更新日期:2020-01-01 00:00:00

  • The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.

    abstract::Evidence of the laboratory benefits of hydroxyurea and its clinical efficacy in reducing acute vaso-occlusive events in adults and children with sickle cell anemia has accumulated for more than 15 years. A definitive clinical trial showing that hydroxyurea can also prevent organ damage might support widespread use of ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.22269

    authors: Thompson BW,Miller ST,Rogers ZR,Rees RC,Ware RE,Waclawiw MA,Iyer RV,Casella JF,Luchtman-Jones L,Rana S,Thornburg CD,Kalpatthi RV,Barredo JC,Brown RC,Sarnaik S,Howard TH,Luck L,Wang WC

    更新日期:2010-02-01 00:00:00

  • The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.

    abstract::Juvenile myelomonocytic leukemia (JMML) is a rare myelodysplastic/myeloproliferative disorder of early childhood characterized by mutations of the RAS-RAF-MAP kinase signaling pathway. We report the case of a child with a diagnosis of JMML carrying two mutations of NRAS gene (c.37G>C and c.38G>A) independently occurri...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23401

    authors: De Filippi P,Zecca M,Novara F,Lisini D,Maserati E,Pasquali F,Rosti V,Carlo-Stella C,Zavras N,Cagioni C,Zuffardi O,Pagliara D,Danesino C,Locatelli F

    更新日期:2012-09-01 00:00:00

  • Treatment of retinoblastoma in Sub-Saharan Africa: Experience of the paediatric oncology unit at Gabriel Toure Teaching Hospital and the Institute of African Tropical Ophthalmology, Bamako, Mali.

    abstract:BACKGROUND:Retinoblastoma (Rb) is the most common intraocular primary malignancy in children. In industrialised countries, the cure rate is about 95%. We present the results of a prospective study on the management of Rb in the paediatric oncology unit of Gabriel Touré Teaching Hospital and African Institute of Tropica...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27101

    authors: Traoré F,Sylla F,Togo B,Kamaté B,Diabaté K,Diakité AA,Diall H,Dicko F,Sylla M,Bey P,Desjardins L,Gagnepain-Lacheteau A,Coze C,Harif M,Doz F

    更新日期:2018-08-01 00:00:00

  • Measurement of energy expenditure.

    abstract::Although investigators have been engaged in the study of human energy metabolism for over 100 years, there remain unanswered questions regarding the role that energy expenditure plays in human health and disease. A critical examination of available methods for measurement of the various components of daily energy expe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23369

    authors: DeLany JP

    更新日期:2012-01-01 00:00:00

  • Significant inconsistency among pediatric oncologists in the use of the neutropenic diet.

    abstract:BACKGROUND:The role of the neutropenic diet in the development of infections in oncology and stem cell transplant (SCT) patients is controversial. There is no data on the use of the neutropenic diet among pediatric oncologists. METHODS:A self-administered electronic survey was sent to 1,639 pediatric oncologists at 19...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25104

    authors: Braun LE,Chen H,Frangoul H

    更新日期:2014-10-01 00:00:00